Arthrogen-CIA 5-clone cocktail kit, 10mg
To Order Contact us: lieven@wlsolutions.be
Carcinoembryonic Antigen, pan (CEA) / CD66; Clone Cocktail (Concentrate) |
||
| RA0491-C.5 | 0.5 ml | EUR 360 |
Carcinoembryonic Antigen, pan (CEA) / CD66; Clone Cocktail (Concentrate) |
||
| RA0491-C1 | 1 ml | EUR 600 |
Anti-Cytokeratin 18 Antibody Clone Cocktail, Unconjugated-100ug |
||
| 3875-MSM8-P1 | 100ug | EUR 513.6 |
Monoclonal Carcinoembryonic Antigen, pan (CEA) / CD66 Antibody, Clone: Cocktail |
||
| AMM00570G | 7 ml | EUR 580.8 |
|
Description: A Monoclonal antibody against Human Carcinoembryonic Antigen, pan (CEA) / CD66. The antibodies are raised in Mouse and are from clone Cocktail. This antibody is applicable in IHC, IF, FC |
||
Anti-Carcinoembryonic Antigen Antibody Clone Cocktail, Unconjugated-100ug |
||
| 1048-MSM9-P1 | 100ug | EUR 513.6 |
p53 Cocktail; Clones Pab 1801 plus DO-7 |
||
| A20093 | 2 ml | EUR 198 |
p53 Cocktail; Clones Pab 1801 plus DO-7 |
||
| A00093 | 6 ml | EUR 338.4 |
p53 Cocktail; Clones Pab 1801 plus DO-7 |
||
| A00093.0025 | 25 ml | EUR 870 |
Monoclonal Cytokeratin 18 (KRT18) Antibody - With BSA and Azide, Clone: Cocktail |
||
| APR14506G | 0.05mg | EUR 475.2 |
|
Description: A Monoclonal antibody against Human Cytokeratin 18 (KRT18) - With BSA and Azide. The antibodies are raised in Mouse and are from clone Cocktail. This antibody is applicable in IHC, IF, FC |
||
Mouse Anti-Human Prostate Cocktail monoclonal antibody, clone JID764 |
||
| CABT-L3014-100uL500uL | 100 uL, 500 uL | EUR 602.4 |
Monoclonal Cytokeratin 18 (KRT18) Antibody - Without BSA and Azide, Clone: Cocktail |
||
| APR14530G | 0.1mg | EUR 580.8 |
|
Description: A Monoclonal antibody against Human Cytokeratin 18 (KRT18) - Without BSA and Azide. The antibodies are raised in Mouse and are from clone Cocktail. This antibody is applicable in IHC, IF, FC |
||
Mouse Anti-Human Cytokeratin Cocktail monoclonal antibody, clone JID670 |
||
| CABT-L2999-100uL500uL | 100 uL, 500 uL | EUR 602.4 |
Anti-Cytokeratin Antibody Clone PAN-CK (Cocktail), Unconjugated-100ug |
||
| MSM17-999-P1 | 100ug | EUR 513.6 |
Monoclonal Cytokeratin, pan (Epithelial Marker) Antibody, Clone: PAN-CK (Cocktail) |
||
| APR14636G | 7 ml | EUR 580.8 |
|
Description: A Monoclonal antibody against Human Cytokeratin, pan (Epithelial Marker). The antibodies are raised in Mouse and are from clone PAN-CK (Cocktail). This antibody is applicable in WB, IHC and IF, FC |
||
Monoclonal Ep-CAM / CD326 (Epithelial Marker) Antibody, Clone: PAN-EpCAM (Cocktail) |
||
| AMM00996G | 7 ml | EUR 580.8 |
|
Description: A Monoclonal antibody against Human Ep-CAM / CD326 (Epithelial Marker). The antibodies are raised in Mouse and are from clone PAN-EpCAM (Cocktail). This antibody is applicable in WB, IHC and IF, FC |
||
Monoclonal Carcinoembryonic Antigen, pan (CEA) / CD66 Antibody - With BSA and Azide, Clone: Cocktail |
||
| AMM00571G | 0.05mg | EUR 475.2 |
|
Description: A Monoclonal antibody against Human Carcinoembryonic Antigen, pan (CEA) / CD66 - With BSA and Azide. The antibodies are raised in Mouse and are from clone Cocktail. This antibody is applicable in IHC, IF, FC |
||
TTF-1 & Cytokeratin 5 Multiplex Cocktail; Clones 8G7G3/1 & EP42 (Ready-To-Use) |
||
| A00145-0002 | 2 ml | EUR 300 |
TTF-1 & Cytokeratin 5 Multiplex Cocktail; Clones 8G7G3/1 & EP42 (Ready-To-Use) |
||
| A00145-0007 | 7 ml | EUR 658.8 |
TTF-1 & Cytokeratin 5 Multiplex Cocktail; Clones 8G7G3/1 & EP42 (Ready-To-Use) |
||
| A00145-0025 | 25 ml | EUR 1857.6 |
Monoclonal Carcinoembryonic Antigen, pan (CEA) / CD66 Antibody - Without BSA and Azide, Clone: Cocktail |
||
| AMM00572G | 0.1mg | EUR 580.8 |
|
Description: A Monoclonal antibody against Human Carcinoembryonic Antigen, pan (CEA) / CD66 - Without BSA and Azide. The antibodies are raised in Mouse and are from clone Cocktail. This antibody is applicable in IHC, IF, FC |
||
Cytokeratin 5,6 Cocktail; Clones EP42 & EP67 (Ready-To-Use) |
||
| A00141-0002 | 2 ml | EUR 321.6 |
Cytokeratin 5,6 Cocktail; Clones EP42 & EP67 (Ready-To-Use) |
||
| A00141-0007 | 7 ml | EUR 712.8 |
Cytokeratin 5,6 Cocktail; Clones EP42 & EP67 (Ready-To-Use) |
||
| A00141-0025 | 25 ml | EUR 2019.6 |
Monoclonal Cytokeratin, pan (Epithelial Marker) Antibody - With BSA and Azide, Clone: PAN-CK (Cocktail) |
||
| APR14619G | 0.05mg | EUR 475.2 |
|
Description: A Monoclonal antibody against Human Cytokeratin, pan (Epithelial Marker) - With BSA and Azide. The antibodies are raised in Mouse and are from clone PAN-CK (Cocktail). This antibody is applicable in WB, IHC and IF, FC |
||
CDX-2 & CEA Multiplex Cocktail; Clones EP25 & COL-1 (Ready-To-Use) |
||
| A00150-0002 | 2 ml | EUR 300 |
CDX-2 & CEA Multiplex Cocktail; Clones EP25 & COL-1 (Ready-To-Use) |
||
| A00150-0007 | 7 ml | EUR 658.8 |
CDX-2 & CEA Multiplex Cocktail; Clones EP25 & COL-1 (Ready-To-Use) |
||
| A00150-0025 | 25 ml | EUR 1856.4 |
Monoclonal Cytokeratin, pan (Epithelial Marker) Antibody - Without BSA and Azide, Clone: PAN-CK (Cocktail) |
||
| APR14623G | 0.1mg | EUR 580.8 |
|
Description: A Monoclonal antibody against Human Cytokeratin, pan (Epithelial Marker) - Without BSA and Azide. The antibodies are raised in Mouse and are from clone PAN-CK (Cocktail). This antibody is applicable in WB, IHC and IF, FC |
||
Monoclonal Ep-CAM / CD326 (Epithelial Marker) Antibody - With BSA and Azide, Clone: PAN-EpCAM (Cocktail) |
||
| AMM00997G | 0.05mg | EUR 475.2 |
|
Description: A Monoclonal antibody against Human Ep-CAM / CD326 (Epithelial Marker) - With BSA and Azide. The antibodies are raised in Mouse and are from clone PAN-EpCAM (Cocktail). This antibody is applicable in WB, IHC and IF, FC |
||
Lineage Cocktail FITC |
||
| 6K01-T050 | 50 tests | EUR 244.8 |
CD5 Antibody Cocktail |
||
| V3133-100UG | 100 ug | EUR 349.3 |
|
Description: Recognizes a 67kDa transmembrane protein, which is identified as CD5. The CD5 antigen is found on 95% of thymocytes and 72% of peripheral blood lymphocytes. In lymph nodes, the main reactivity is observed in T cell areas. Anti-CD5 is a pan T-cell marker that also reacts with a range of neoplastic B-cells, e.g. chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma, and a subset (~10%) of diffuse large B-cell lymphoma. CD5 aberrant expression is useful in making a diagnosis of mature T-cell neoplasms. Anti-CD5 detection is diagnostic in CLL/SLL within a panel of other B-cell markers, especially one that includes anti-CD23. Anti-CD5 is also very useful in differentiating among mature small lymphoid cell malignancies. In addition, anti-CD5 can be used in distinguishing thymic carcinoma (+) from thymoma (-). Anti-CD5 does not react with granulocytes or monocytes. |
||
CD5 Antibody Cocktail |
||
| V3133-20UG | 20 ug | EUR 153.3 |
|
Description: Recognizes a 67kDa transmembrane protein, which is identified as CD5. The CD5 antigen is found on 95% of thymocytes and 72% of peripheral blood lymphocytes. In lymph nodes, the main reactivity is observed in T cell areas. Anti-CD5 is a pan T-cell marker that also reacts with a range of neoplastic B-cells, e.g. chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma, and a subset (~10%) of diffuse large B-cell lymphoma. CD5 aberrant expression is useful in making a diagnosis of mature T-cell neoplasms. Anti-CD5 detection is diagnostic in CLL/SLL within a panel of other B-cell markers, especially one that includes anti-CD23. Anti-CD5 is also very useful in differentiating among mature small lymphoid cell malignancies. In addition, anti-CD5 can be used in distinguishing thymic carcinoma (+) from thymoma (-). Anti-CD5 does not react with granulocytes or monocytes. |
||
CD5 Antibody Cocktail |
||
| V3133IHC-7ML | 7 ml | EUR 349.3 |
|
Description: Recognizes a 67kDa transmembrane protein, which is identified as CD5. The CD5 antigen is found on 95% of thymocytes and 72% of peripheral blood lymphocytes. In lymph nodes, the main reactivity is observed in T cell areas. Anti-CD5 is a pan T-cell marker that also reacts with a range of neoplastic B-cells, e.g. chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma, and a subset (~10%) of diffuse large B-cell lymphoma. CD5 aberrant expression is useful in making a diagnosis of mature T-cell neoplasms. Anti-CD5 detection is diagnostic in CLL/SLL within a panel of other B-cell markers, especially one that includes anti-CD23. Anti-CD5 is also very useful in differentiating among mature small lymphoid cell malignancies. In addition, anti-CD5 can be used in distinguishing thymic carcinoma (+) from thymoma (-). Anti-CD5 does not react with granulocytes or monocytes. |
||
CD5 Antibody Cocktail |
||
| V3133SAF-100UG | 100 ug | EUR 349.3 |
|
Description: Recognizes a 67kDa transmembrane protein, which is identified as CD5. The CD5 antigen is found on 95% of thymocytes and 72% of peripheral blood lymphocytes. In lymph nodes, the main reactivity is observed in T cell areas. Anti-CD5 is a pan T-cell marker that also reacts with a range of neoplastic B-cells, e.g. chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma, and a subset (~10%) of diffuse large B-cell lymphoma. CD5 aberrant expression is useful in making a diagnosis of mature T-cell neoplasms. Anti-CD5 detection is diagnostic in CLL/SLL within a panel of other B-cell markers, especially one that includes anti-CD23. Anti-CD5 is also very useful in differentiating among mature small lymphoid cell malignancies. In addition, anti-CD5 can be used in distinguishing thymic carcinoma (+) from thymoma (-). Anti-CD5 does not react with granulocytes or monocytes. |
||
CD6 Antibody Cocktail |
||
| V2041-100UG | 100 ug | EUR 349.3 |
|
Description: CD6 is a type I transmembrane glycoprotein that contains a 24-amino acid signal sequence, three extracellular “scavenger receptor cysteine-rich” (SRCR) domains, a membrane-spanning domain and a 44-amino acid cytoplasmic domain. The CD6 glycoprotein is tyrosine phosphorylated during TCR-mediated T cell activation. CD6 shows significant homology to CD5. CD6 is present on mature thymocytes, peripheral T cells and a subset of B cells. antibody to CD6 can be used to deplete T cells from bone marrow transplants to prevent graft versus host disease. |
||
CD6 Antibody Cocktail |
||
| V2041-20UG | 20 ug | EUR 153.3 |
|
Description: CD6 is a type I transmembrane glycoprotein that contains a 24-amino acid signal sequence, three extracellular “scavenger receptor cysteine-rich” (SRCR) domains, a membrane-spanning domain and a 44-amino acid cytoplasmic domain. The CD6 glycoprotein is tyrosine phosphorylated during TCR-mediated T cell activation. CD6 shows significant homology to CD5. CD6 is present on mature thymocytes, peripheral T cells and a subset of B cells. antibody to CD6 can be used to deplete T cells from bone marrow transplants to prevent graft versus host disease. |
||
CD6 Antibody Cocktail |
||
| V2041IHC-7ML | 7 ml | EUR 349.3 |
|
Description: CD6 is a type I transmembrane glycoprotein that contains a 24-amino acid signal sequence, three extracellular “scavenger receptor cysteine-rich” (SRCR) domains, a membrane-spanning domain and a 44-amino acid cytoplasmic domain. The CD6 glycoprotein is tyrosine phosphorylated during TCR-mediated T cell activation. CD6 shows significant homology to CD5. CD6 is present on mature thymocytes, peripheral T cells and a subset of B cells. antibody to CD6 can be used to deplete T cells from bone marrow transplants to prevent graft versus host disease. |
||
CD6 Antibody Cocktail |
||
| V2041SAF-100UG | 100 ug | EUR 349.3 |
|
Description: CD6 is a type I transmembrane glycoprotein that contains a 24-amino acid signal sequence, three extracellular “scavenger receptor cysteine-rich” (SRCR) domains, a membrane-spanning domain and a 44-amino acid cytoplasmic domain. The CD6 glycoprotein is tyrosine phosphorylated during TCR-mediated T cell activation. CD6 shows significant homology to CD5. CD6 is present on mature thymocytes, peripheral T cells and a subset of B cells. antibody to CD6 can be used to deplete T cells from bone marrow transplants to prevent graft versus host disease. |
||
CEA Antibody Cocktail |
||
| V2090-100UG | 100 ug | EUR 349.3 |
|
Description: This antibody cocktail recognizes proteins of 80-200kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody cocktail shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
||
CEA Antibody Cocktail |
||
| V2090-20UG | 20 ug | EUR 153.3 |
|
Description: This antibody cocktail recognizes proteins of 80-200kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody cocktail shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
||
CEA Antibody Cocktail |
||
| V2090IHC-7ML | 7 ml | EUR 349.3 |
|
Description: This antibody cocktail recognizes proteins of 80-200kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody cocktail shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
||
CEA Antibody Cocktail |
||
| V2090SAF-100UG | 100 ug | EUR 349.3 |
|
Description: This antibody cocktail recognizes proteins of 80-200kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody cocktail shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
||
CD8A Antibody Cocktail |
||
| V3134-100UG | 100 ug | EUR 349.3 |
|
Description: CD8 is a cell surface receptor expressed either as a heterodimer with the CD8 beta chain (CD8a/b) or as a homodimer (CD8a/a). A majority of thymocytes and a subpopulation of mature T cells and NK cells express CD8a. CD8 binds to MHC class 1 and through its association with protein tyrosine kinase p56lck plays a role in T cell development and activation of mature T cells. For mature T-cells, CD4 and CD8 are mutually exclusive, so anti-CD8, generally used in conjunction with anti-CD4. It is a useful marker for distinguishing helper/inducer T-lymphocytes, and most peripheral T-cell lymphomas are CD4+/CD8-. Anaplastic large cell lymphoma is usually CD4+ and CD8-, and in T-lymphoblastic lymphoma/leukemia, CD4 and CD8 are often co-expressed. CD8 is also found in littoral cell angioma of the spleen. |
||
CD8A Antibody Cocktail |
||
| V3134-20UG | 20 ug | EUR 153.3 |
|
Description: CD8 is a cell surface receptor expressed either as a heterodimer with the CD8 beta chain (CD8a/b) or as a homodimer (CD8a/a). A majority of thymocytes and a subpopulation of mature T cells and NK cells express CD8a. CD8 binds to MHC class 1 and through its association with protein tyrosine kinase p56lck plays a role in T cell development and activation of mature T cells. For mature T-cells, CD4 and CD8 are mutually exclusive, so anti-CD8, generally used in conjunction with anti-CD4. It is a useful marker for distinguishing helper/inducer T-lymphocytes, and most peripheral T-cell lymphomas are CD4+/CD8-. Anaplastic large cell lymphoma is usually CD4+ and CD8-, and in T-lymphoblastic lymphoma/leukemia, CD4 and CD8 are often co-expressed. CD8 is also found in littoral cell angioma of the spleen. |
||
CD8A Antibody Cocktail |
||
| V3134IHC-7ML | 7 ml | EUR 349.3 |
|
Description: CD8 is a cell surface receptor expressed either as a heterodimer with the CD8 beta chain (CD8a/b) or as a homodimer (CD8a/a). A majority of thymocytes and a subpopulation of mature T cells and NK cells express CD8a. CD8 binds to MHC class 1 and through its association with protein tyrosine kinase p56lck plays a role in T cell development and activation of mature T cells. For mature T-cells, CD4 and CD8 are mutually exclusive, so anti-CD8, generally used in conjunction with anti-CD4. It is a useful marker for distinguishing helper/inducer T-lymphocytes, and most peripheral T-cell lymphomas are CD4+/CD8-. Anaplastic large cell lymphoma is usually CD4+ and CD8-, and in T-lymphoblastic lymphoma/leukemia, CD4 and CD8 are often co-expressed. CD8 is also found in littoral cell angioma of the spleen. |
||
CD8A Antibody Cocktail |
||
| V3134SAF-100UG | 100 ug | EUR 349.3 |
|
Description: CD8 is a cell surface receptor expressed either as a heterodimer with the CD8 beta chain (CD8a/b) or as a homodimer (CD8a/a). A majority of thymocytes and a subpopulation of mature T cells and NK cells express CD8a. CD8 binds to MHC class 1 and through its association with protein tyrosine kinase p56lck plays a role in T cell development and activation of mature T cells. For mature T-cells, CD4 and CD8 are mutually exclusive, so anti-CD8, generally used in conjunction with anti-CD4. It is a useful marker for distinguishing helper/inducer T-lymphocytes, and most peripheral T-cell lymphomas are CD4+/CD8-. Anaplastic large cell lymphoma is usually CD4+ and CD8-, and in T-lymphoblastic lymphoma/leukemia, CD4 and CD8 are often co-expressed. CD8 is also found in littoral cell angioma of the spleen. |
||
PAX8 Antibody Cocktail |
||
| V3414-100UG | 100 ug | EUR 349.3 |
|
Description: PAX8 is a member of the paired box (PAX) family of transcription factors. This nuclear protein is involved in thyroid follicular cell development and expression of thyroid-specific genes. Mutations in this gene have been associated with thyroid dysgenesis, thyroid follicular carcinomas, and atypical thyroid adenomas. PAX8 is expressed in the thyroid (and associated carcinomas), non-ciliated mucosal cells of the fallopian tubes, and simple ovarian inclusion cysts, but not normal ovarian surface epithelial cells. PAX8 is expressed in a high percentage of ovarian serous, endometrioid, and clear cell carcinomas, but only rarely in primary ovarian mucinous adenocarcinomas. PAX-8 expression is reported in renal tubules as well as renal cell carcinoma, nephroblastoma, and seminoma. PAX8 antibody may be used as an additional immunohistochemical marker for renal epithelial tumors. |
||
PAX8 Antibody Cocktail |
||
| V3414-20UG | 20 ug | EUR 153.3 |
|
Description: PAX8 is a member of the paired box (PAX) family of transcription factors. This nuclear protein is involved in thyroid follicular cell development and expression of thyroid-specific genes. Mutations in this gene have been associated with thyroid dysgenesis, thyroid follicular carcinomas, and atypical thyroid adenomas. PAX8 is expressed in the thyroid (and associated carcinomas), non-ciliated mucosal cells of the fallopian tubes, and simple ovarian inclusion cysts, but not normal ovarian surface epithelial cells. PAX8 is expressed in a high percentage of ovarian serous, endometrioid, and clear cell carcinomas, but only rarely in primary ovarian mucinous adenocarcinomas. PAX-8 expression is reported in renal tubules as well as renal cell carcinoma, nephroblastoma, and seminoma. PAX8 antibody may be used as an additional immunohistochemical marker for renal epithelial tumors. |
||
PAX8 Antibody Cocktail |
||
| V3414SAF-100UG | 100 ug | EUR 349.3 |
|
Description: PAX8 is a member of the paired box (PAX) family of transcription factors. This nuclear protein is involved in thyroid follicular cell development and expression of thyroid-specific genes. Mutations in this gene have been associated with thyroid dysgenesis, thyroid follicular carcinomas, and atypical thyroid adenomas. PAX8 is expressed in the thyroid (and associated carcinomas), non-ciliated mucosal cells of the fallopian tubes, and simple ovarian inclusion cysts, but not normal ovarian surface epithelial cells. PAX8 is expressed in a high percentage of ovarian serous, endometrioid, and clear cell carcinomas, but only rarely in primary ovarian mucinous adenocarcinomas. PAX-8 expression is reported in renal tubules as well as renal cell carcinoma, nephroblastoma, and seminoma. PAX8 antibody may be used as an additional immunohistochemical marker for renal epithelial tumors. |
||
CD1a Antibody Cocktail |
||
| V2027-100UG | 100 ug | EUR 349.3 |
|
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
||
CD1a Antibody Cocktail |
||
| V2027-20UG | 20 ug | EUR 153.3 |
|
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
||
CD1a Antibody Cocktail |
||
| V2027IHC-7ML | 7 ml | EUR 349.3 |
|
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
||
CD1a Antibody Cocktail |
||
| V2027SAF-100UG | 100 ug | EUR 349.3 |
|
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
||
CD68 Antibody Cocktail |
||
| V2075-100UG | 100 ug | EUR 349.3 |
|
Description: This antibody cocktail recognizes a glycoprotein of 110kDa, which is identified as CD68. antibody to CD68 is important for identifying macrophages in tissue sections. It stains macrophages in a wide variety of human tissues, including Kupffer cells and macrophages in the red pulp of the spleen, in lamina propria of the gut, in lung alveoli, and in bone marrow. CD68 antibody reacts with myeloid precursors and peripheral blood granulocytes. It also reacts with plasmacytoid T cells, which are supposed to be of monocyte/macrophage origin. CD68 shows strong granular cytoplasmic staining of chronic and acute myeloid leukemia and also reacts with rare cases of true histiocytic neoplasia. Lymphomas are negative or show few granules. |
||
CD68 Antibody Cocktail |
||
| V2075-20UG | 20 ug | EUR 153.3 |
|
Description: This antibody cocktail recognizes a glycoprotein of 110kDa, which is identified as CD68. antibody to CD68 is important for identifying macrophages in tissue sections. It stains macrophages in a wide variety of human tissues, including Kupffer cells and macrophages in the red pulp of the spleen, in lamina propria of the gut, in lung alveoli, and in bone marrow. CD68 antibody reacts with myeloid precursors and peripheral blood granulocytes. It also reacts with plasmacytoid T cells, which are supposed to be of monocyte/macrophage origin. CD68 shows strong granular cytoplasmic staining of chronic and acute myeloid leukemia and also reacts with rare cases of true histiocytic neoplasia. Lymphomas are negative or show few granules. |
||
CD68 Antibody Cocktail |
||
| V2075IHC-7ML | 7 ml | EUR 349.3 |
|
Description: This antibody cocktail recognizes a glycoprotein of 110kDa, which is identified as CD68. antibody to CD68 is important for identifying macrophages in tissue sections. It stains macrophages in a wide variety of human tissues, including Kupffer cells and macrophages in the red pulp of the spleen, in lamina propria of the gut, in lung alveoli, and in bone marrow. CD68 antibody reacts with myeloid precursors and peripheral blood granulocytes. It also reacts with plasmacytoid T cells, which are supposed to be of monocyte/macrophage origin. CD68 shows strong granular cytoplasmic staining of chronic and acute myeloid leukemia and also reacts with rare cases of true histiocytic neoplasia. Lymphomas are negative or show few granules. |
||
CD68 Antibody Cocktail |
||
| V2075SAF-100UG | 100 ug | EUR 349.3 |
|
Description: This antibody cocktail recognizes a glycoprotein of 110kDa, which is identified as CD68. antibody to CD68 is important for identifying macrophages in tissue sections. It stains macrophages in a wide variety of human tissues, including Kupffer cells and macrophages in the red pulp of the spleen, in lamina propria of the gut, in lung alveoli, and in bone marrow. CD68 antibody reacts with myeloid precursors and peripheral blood granulocytes. It also reacts with plasmacytoid T cells, which are supposed to be of monocyte/macrophage origin. CD68 shows strong granular cytoplasmic staining of chronic and acute myeloid leukemia and also reacts with rare cases of true histiocytic neoplasia. Lymphomas are negative or show few granules. |
||
CD45 Antibody Cocktail |
||
| V2243-100UG | 100 ug | EUR 349.3 |
|
Description: This antibody cocktail contains an antibody which binds to all CD45 leukocyte common antigen (LCA) family isoforms (clone 2B11), and an antibody specific to the CD45RB isoform (clone PD7/26). CD45 is expressed on hematopoietic cell lines but absent on non-hematopoietic cell lines, normal and malignant non-hematopoietic tissues. The intracellular portions of the CD45 isoforms have protein phosphatase activity and are involved in regulation of transmembrane signals. antibody to CD45 is useful in differential diagnosis of lymphoid tumors from non-hematopoietic undifferentiated neoplasms. A positive result with this antibody cocktail is highly indicative of lymphoid or myeloid origin. Certain types of lymphoid neoplasms may lack CD45 (Hodgkin lymphoma, some T-cell lymphomas, and some leukemias) so its absence does not rule out a hematolymphoid tumor. This antibody cocktail detects CD45 expressed almost exclusively by cells of hematopoietic lineage and is present in most benign and malignant lymphocytes as well as plasma cell precursors. |
||
CD45 Antibody Cocktail |
||
| V2243-20UG | 20 ug | EUR 153.3 |
|
Description: This antibody cocktail contains an antibody which binds to all CD45 leukocyte common antigen (LCA) family isoforms (clone 2B11), and an antibody specific to the CD45RB isoform (clone PD7/26). CD45 is expressed on hematopoietic cell lines but absent on non-hematopoietic cell lines, normal and malignant non-hematopoietic tissues. The intracellular portions of the CD45 isoforms have protein phosphatase activity and are involved in regulation of transmembrane signals. antibody to CD45 is useful in differential diagnosis of lymphoid tumors from non-hematopoietic undifferentiated neoplasms. A positive result with this antibody cocktail is highly indicative of lymphoid or myeloid origin. Certain types of lymphoid neoplasms may lack CD45 (Hodgkin lymphoma, some T-cell lymphomas, and some leukemias) so its absence does not rule out a hematolymphoid tumor. This antibody cocktail detects CD45 expressed almost exclusively by cells of hematopoietic lineage and is present in most benign and malignant lymphocytes as well as plasma cell precursors. |
||
CD45 Antibody Cocktail |
||
| V2243IHC-7ML | 7 ml | EUR 349.3 |
|
Description: This antibody cocktail contains an antibody which binds to all CD45 leukocyte common antigen (LCA) family isoforms (clone 2B11), and an antibody specific to the CD45RB isoform (clone PD7/26). CD45 is expressed on hematopoietic cell lines but absent on non-hematopoietic cell lines, normal and malignant non-hematopoietic tissues. The intracellular portions of the CD45 isoforms have protein phosphatase activity and are involved in regulation of transmembrane signals. antibody to CD45 is useful in differential diagnosis of lymphoid tumors from non-hematopoietic undifferentiated neoplasms. A positive result with this antibody cocktail is highly indicative of lymphoid or myeloid origin. Certain types of lymphoid neoplasms may lack CD45 (Hodgkin lymphoma, some T-cell lymphomas, and some leukemias) so its absence does not rule out a hematolymphoid tumor. This antibody cocktail detects CD45 expressed almost exclusively by cells of hematopoietic lineage and is present in most benign and malignant lymphocytes as well as plasma cell precursors. |
||
CD45 Antibody Cocktail |
||
| V2243SAF-100UG | 100 ug | EUR 349.3 |
|
Description: This antibody cocktail contains an antibody which binds to all CD45 leukocyte common antigen (LCA) family isoforms (clone 2B11), and an antibody specific to the CD45RB isoform (clone PD7/26). CD45 is expressed on hematopoietic cell lines but absent on non-hematopoietic cell lines, normal and malignant non-hematopoietic tissues. The intracellular portions of the CD45 isoforms have protein phosphatase activity and are involved in regulation of transmembrane signals. antibody to CD45 is useful in differential diagnosis of lymphoid tumors from non-hematopoietic undifferentiated neoplasms. A positive result with this antibody cocktail is highly indicative of lymphoid or myeloid origin. Certain types of lymphoid neoplasms may lack CD45 (Hodgkin lymphoma, some T-cell lymphomas, and some leukemias) so its absence does not rule out a hematolymphoid tumor. This antibody cocktail detects CD45 expressed almost exclusively by cells of hematopoietic lineage and is present in most benign and malignant lymphocytes as well as plasma cell precursors. |
||
CD20 Antibody Cocktail |
||
| V2392-0.1ML | 0.1 ml | EUR 153.3 |
|
Description: This antibody recognizes a protein of 33-37kDa, identified as CD20 (Workshop V; Code CD20.12). The antibody recognizes the extracellular domain of the protein. The epitope is similar to or identical to that recognized by other CD20 antibodies including Leu-16 and B1. This antibody can be used for immunophenotyping of leukemia and malignant cells, B lymphocyte detection in peripheral blood, Bcell localization in tissues and B lymphocyte purification by immunosorbent methods. CD20 is a non-Ig differentiation antigen of Bcells and its expression is restricted to normal and neoplastic Bcells, being absent from all other leukocytes and tissues. It is expressed by pre Bcells and persists during all stages of Bcell maturation but is lost upon terminal differentiation into plasma cells. Protein passes through the membrane 4 times with both ends in cytoplasm and exposes one short and one longer loop to the external environment. CD20 is not glycosylated in resting Bcells and its cytoplasmic domains are differentially phosphorylated upon activation. It acts as a calcium channel involved in Bcell activation and cell cycle progression. |
||
CD20 Antibody Cocktail |
||
| V2392-0.5ML | 0.5 ml | EUR 349.3 |
|
Description: This antibody recognizes a protein of 33-37kDa, identified as CD20 (Workshop V; Code CD20.12). The antibody recognizes the extracellular domain of the protein. The epitope is similar to or identical to that recognized by other CD20 antibodies including Leu-16 and B1. This antibody can be used for immunophenotyping of leukemia and malignant cells, B lymphocyte detection in peripheral blood, Bcell localization in tissues and B lymphocyte purification by immunosorbent methods. CD20 is a non-Ig differentiation antigen of Bcells and its expression is restricted to normal and neoplastic Bcells, being absent from all other leukocytes and tissues. It is expressed by pre Bcells and persists during all stages of Bcell maturation but is lost upon terminal differentiation into plasma cells. Protein passes through the membrane 4 times with both ends in cytoplasm and exposes one short and one longer loop to the external environment. CD20 is not glycosylated in resting Bcells and its cytoplasmic domains are differentially phosphorylated upon activation. It acts as a calcium channel involved in Bcell activation and cell cycle progression. |
||
CD99 Antibody Cocktail |
||
| V2711S-0.1ML | 0.1 ml | EUR 153.3 |
|
Description: Recognizes a sialoglycoprotein of 27-32kDa, identified as CD99, or MIC2 gene product, or E2 antigen. MIC2 gene is located in the pseudo-autosomal region of the human X and Y chromosome. MIC2 gene encodes two distinct proteins, which are produced by alternative splicing of the CD99 gene transcript and are identified as bands of 30 and 32kDa (p30/32). Although its function is not fully understood, CD99 is implicated in various cellular processes including homotypic aggregation of T cells, upregulation of T cell receptor and MHS molecules, apoptosis of immature thymocytes and leukocyte diapedesis. CD99 is expressed on the cell membrane of some lymphocytes, cortical thymocytes, and granulosa cells of the ovary. Most pancreatic islet cells, Sertoli cells of the testis, and some endothelial cells express this antigen. Mature granulocytes express very little or no CD99. MIC2 is strongly expressed on Ewing's sarcoma cells and primitive peripheral neuroectodermal tumors. |
||
CD99 Antibody Cocktail |
||
| V2711S-0.5ML | 0.5 ml | EUR 349.3 |
|
Description: Recognizes a sialoglycoprotein of 27-32kDa, identified as CD99, or MIC2 gene product, or E2 antigen. MIC2 gene is located in the pseudo-autosomal region of the human X and Y chromosome. MIC2 gene encodes two distinct proteins, which are produced by alternative splicing of the CD99 gene transcript and are identified as bands of 30 and 32kDa (p30/32). Although its function is not fully understood, CD99 is implicated in various cellular processes including homotypic aggregation of T cells, upregulation of T cell receptor and MHS molecules, apoptosis of immature thymocytes and leukocyte diapedesis. CD99 is expressed on the cell membrane of some lymphocytes, cortical thymocytes, and granulosa cells of the ovary. Most pancreatic islet cells, Sertoli cells of the testis, and some endothelial cells express this antigen. Mature granulocytes express very little or no CD99. MIC2 is strongly expressed on Ewing's sarcoma cells and primitive peripheral neuroectodermal tumors. |
||
MITF Antibody Cocktail |
||
| V2715-100UG | 100 ug | EUR 349.3 |
|
Description: MITF (microphthalmia transcription factor) is a basic helix-loop-helix-leucine-zipper (bHLH-Zip) transcription factor that regulates the development and survival of melanocytes and retinal pigment epithelium, and also is involved in transcription of pigmentation enzyme genes such as tyrosinase TRP1 and TRP2. MITF has been shown to be phosphorylated by MAP kinase in response to c-kit activation, resulting in upregulation of MITF transcriptional activity. Mutations of the MITF gene are associated with the autosomal dominant hereditary deafness and pigmentation condition, Waardenburg Syndrome type 2A. Multiple isoforms of MITF exist, including MITF-A, MITF-B, MITF-C, MITF-H, and MITF-M, which differ in the amino-terminal domain and in their expression patterns. The MITF-M isoform is restricted to the melanocyte cell lineage. Anti-MITF, D5, recognizes a nuclear protein, which is expressed in the majority of primary and metastatic epithelioid malignant melanomas as well as in normal melanocytes, benign nevi and dysplastic nevi. |
||
MITF Antibody Cocktail |
||
| V2715-20UG | 20 ug | EUR 153.3 |
|
Description: MITF (microphthalmia transcription factor) is a basic helix-loop-helix-leucine-zipper (bHLH-Zip) transcription factor that regulates the development and survival of melanocytes and retinal pigment epithelium, and also is involved in transcription of pigmentation enzyme genes such as tyrosinase TRP1 and TRP2. MITF has been shown to be phosphorylated by MAP kinase in response to c-kit activation, resulting in upregulation of MITF transcriptional activity. Mutations of the MITF gene are associated with the autosomal dominant hereditary deafness and pigmentation condition, Waardenburg Syndrome type 2A. Multiple isoforms of MITF exist, including MITF-A, MITF-B, MITF-C, MITF-H, and MITF-M, which differ in the amino-terminal domain and in their expression patterns. The MITF-M isoform is restricted to the melanocyte cell lineage. Anti-MITF, D5, recognizes a nuclear protein, which is expressed in the majority of primary and metastatic epithelioid malignant melanomas as well as in normal melanocytes, benign nevi and dysplastic nevi. |
||
MITF Antibody Cocktail |
||
| V2715IHC-7ML | 7 ml | EUR 349.3 |
|
Description: MITF (microphthalmia transcription factor) is a basic helix-loop-helix-leucine-zipper (bHLH-Zip) transcription factor that regulates the development and survival of melanocytes and retinal pigment epithelium, and also is involved in transcription of pigmentation enzyme genes such as tyrosinase TRP1 and TRP2. MITF has been shown to be phosphorylated by MAP kinase in response to c-kit activation, resulting in upregulation of MITF transcriptional activity. Mutations of the MITF gene are associated with the autosomal dominant hereditary deafness and pigmentation condition, Waardenburg Syndrome type 2A. Multiple isoforms of MITF exist, including MITF-A, MITF-B, MITF-C, MITF-H, and MITF-M, which differ in the amino-terminal domain and in their expression patterns. The MITF-M isoform is restricted to the melanocyte cell lineage. Anti-MITF, D5, recognizes a nuclear protein, which is expressed in the majority of primary and metastatic epithelioid malignant melanomas as well as in normal melanocytes, benign nevi and dysplastic nevi. |
||
MITF Antibody Cocktail |
||
| V2715SAF-100UG | 100 ug | EUR 349.3 |
|
Description: MITF (microphthalmia transcription factor) is a basic helix-loop-helix-leucine-zipper (bHLH-Zip) transcription factor that regulates the development and survival of melanocytes and retinal pigment epithelium, and also is involved in transcription of pigmentation enzyme genes such as tyrosinase TRP1 and TRP2. MITF has been shown to be phosphorylated by MAP kinase in response to c-kit activation, resulting in upregulation of MITF transcriptional activity. Mutations of the MITF gene are associated with the autosomal dominant hereditary deafness and pigmentation condition, Waardenburg Syndrome type 2A. Multiple isoforms of MITF exist, including MITF-A, MITF-B, MITF-C, MITF-H, and MITF-M, which differ in the amino-terminal domain and in their expression patterns. The MITF-M isoform is restricted to the melanocyte cell lineage. Anti-MITF, D5, recognizes a nuclear protein, which is expressed in the majority of primary and metastatic epithelioid malignant melanomas as well as in normal melanocytes, benign nevi and dysplastic nevi. |
||
CD30 Antibody Cocktail |
||
| V2994S-0.1ML | 0.1 ml | EUR 153.3 |
|
Description: Recognizes a single chain glycoprotein of 105/120kDa, identified as CD30/Ki-1. CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kDa glycoprotein. In Hodgkin's disease, CD30/Ki-1 antigen is expressed by mononuclear-Hodgkin and multinucleated Reed-Sternberg cells. It is also expressed by the tumor cells of a majority of anaplastic large cell lymphomas as well as by a varying proportion of activated T and B cells. This mAb distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas. About one third of the Ki-1 positive lymphomas lack the leukocyte common antigen (CD45). |
||
CD30 Antibody Cocktail |
||
| V2994S-0.5ML | 0.5 ml | EUR 349.3 |
|
Description: Recognizes a single chain glycoprotein of 105/120kDa, identified as CD30/Ki-1. CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kDa glycoprotein. In Hodgkin's disease, CD30/Ki-1 antigen is expressed by mononuclear-Hodgkin and multinucleated Reed-Sternberg cells. It is also expressed by the tumor cells of a majority of anaplastic large cell lymphomas as well as by a varying proportion of activated T and B cells. This mAb distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas. About one third of the Ki-1 positive lymphomas lack the leukocyte common antigen (CD45). |
||
CD34 Antibody Cocktail |
||
| V2999-100UG | 100 ug | EUR 349.3 |
|
Description: This antibody recognizes a carbohydrate epitope on a single chain, transmembrane, heavily glycosylated protein of 90-120kDa, which is identified as CD34 (VI international workshop on human differentiation antigens). Its expression is a hallmark for identifying pluripotent hematopoietic stem or progenitor cells. Its expression is gradually lost as lineage committed progenitors differentiate. CD34 is a marker of choice for staining blasts in acute myeloid leukemia. In addition, it is expressed by soft tissue tumors, such as solitary fibrous tumor and gastrointestinal stromal tumor. CD34 expression is also found in vascular endothelium. Additionally, proliferating endothelial cells overexpress this molecule than the non-proliferating endothelial cells. Anti-CD34 labels > 85% of angiosarcoma and Kaposi s sarcoma, but shows low specificity. |
||
CD34 Antibody Cocktail |
||
| V2999-20UG | 20 ug | EUR 153.3 |
|
Description: This antibody recognizes a carbohydrate epitope on a single chain, transmembrane, heavily glycosylated protein of 90-120kDa, which is identified as CD34 (VI international workshop on human differentiation antigens). Its expression is a hallmark for identifying pluripotent hematopoietic stem or progenitor cells. Its expression is gradually lost as lineage committed progenitors differentiate. CD34 is a marker of choice for staining blasts in acute myeloid leukemia. In addition, it is expressed by soft tissue tumors, such as solitary fibrous tumor and gastrointestinal stromal tumor. CD34 expression is also found in vascular endothelium. Additionally, proliferating endothelial cells overexpress this molecule than the non-proliferating endothelial cells. Anti-CD34 labels > 85% of angiosarcoma and Kaposi s sarcoma, but shows low specificity. |
||
CD34 Antibody Cocktail |
||
| V2999IHC-7ML | 7 ml | EUR 349.3 |
|
Description: This antibody recognizes a carbohydrate epitope on a single chain, transmembrane, heavily glycosylated protein of 90-120kDa, which is identified as CD34 (VI international workshop on human differentiation antigens). Its expression is a hallmark for identifying pluripotent hematopoietic stem or progenitor cells. Its expression is gradually lost as lineage committed progenitors differentiate. CD34 is a marker of choice for staining blasts in acute myeloid leukemia. In addition, it is expressed by soft tissue tumors, such as solitary fibrous tumor and gastrointestinal stromal tumor. CD34 expression is also found in vascular endothelium. Additionally, proliferating endothelial cells overexpress this molecule than the non-proliferating endothelial cells. Anti-CD34 labels > 85% of angiosarcoma and Kaposi s sarcoma, but shows low specificity. |
||
CD34 Antibody Cocktail |
||
| V2999SAF-100UG | 100 ug | EUR 349.3 |
|
Description: This antibody recognizes a carbohydrate epitope on a single chain, transmembrane, heavily glycosylated protein of 90-120kDa, which is identified as CD34 (VI international workshop on human differentiation antigens). Its expression is a hallmark for identifying pluripotent hematopoietic stem or progenitor cells. Its expression is gradually lost as lineage committed progenitors differentiate. CD34 is a marker of choice for staining blasts in acute myeloid leukemia. In addition, it is expressed by soft tissue tumors, such as solitary fibrous tumor and gastrointestinal stromal tumor. CD34 expression is also found in vascular endothelium. Additionally, proliferating endothelial cells overexpress this molecule than the non-proliferating endothelial cells. Anti-CD34 labels > 85% of angiosarcoma and Kaposi s sarcoma, but shows low specificity. |
||
CD99 Antibody Cocktail |
||
| V7952-100UG | 100 ug | EUR 349.3 |
|
Description: Recognizes a sialoglycoprotein of 27-32kDa, identified as CD99, or MIC2 gene product, or E2 antigen. MIC2 gene is located in the pseudo-autosomal region of the human X and Y chromosome. MIC2 gene encodes two distinct proteins, which are produced by alternative splicing of the CD99 gene transcript and are identified as bands of 30 and 32kDa (p30/32).Although its function is not fully understood, CD99 is implicated in various cellular processes including homotypic aggregation of T cells, upregulation of T cell receptor and MHS molecules, apoptosis of immature thymocytes and leukocyte diapedesis.CD99 is expressed on the cell membrane of some lymphocytes, cortical thymocytes, and granulosa cells of the ovary. Most pancreatic islet cells, Sertoli cells of the testis, and some endothelial cells express this antigen. Mature granulocytes express very little or no CD99. MIC2 is strongly expressed on Ewing's sarcoma cells and primitive peripheral neuroectodermal tumors. |
||
CD99 Antibody Cocktail |
||
| V7952-20UG | 20 ug | EUR 153.3 |
|
Description: Recognizes a sialoglycoprotein of 27-32kDa, identified as CD99, or MIC2 gene product, or E2 antigen. MIC2 gene is located in the pseudo-autosomal region of the human X and Y chromosome. MIC2 gene encodes two distinct proteins, which are produced by alternative splicing of the CD99 gene transcript and are identified as bands of 30 and 32kDa (p30/32).Although its function is not fully understood, CD99 is implicated in various cellular processes including homotypic aggregation of T cells, upregulation of T cell receptor and MHS molecules, apoptosis of immature thymocytes and leukocyte diapedesis.CD99 is expressed on the cell membrane of some lymphocytes, cortical thymocytes, and granulosa cells of the ovary. Most pancreatic islet cells, Sertoli cells of the testis, and some endothelial cells express this antigen. Mature granulocytes express very little or no CD99. MIC2 is strongly expressed on Ewing's sarcoma cells and primitive peripheral neuroectodermal tumors. |
||
CD99 Antibody Cocktail |
||
| V7952SAF-100UG | 100 ug | EUR 349.3 |
|
Description: Recognizes a sialoglycoprotein of 27-32kDa, identified as CD99, or MIC2 gene product, or E2 antigen. MIC2 gene is located in the pseudo-autosomal region of the human X and Y chromosome. MIC2 gene encodes two distinct proteins, which are produced by alternative splicing of the CD99 gene transcript and are identified as bands of 30 and 32kDa (p30/32).Although its function is not fully understood, CD99 is implicated in various cellular processes including homotypic aggregation of T cells, upregulation of T cell receptor and MHS molecules, apoptosis of immature thymocytes and leukocyte diapedesis.CD99 is expressed on the cell membrane of some lymphocytes, cortical thymocytes, and granulosa cells of the ovary. Most pancreatic islet cells, Sertoli cells of the testis, and some endothelial cells express this antigen. Mature granulocytes express very little or no CD99. MIC2 is strongly expressed on Ewing's sarcoma cells and primitive peripheral neuroectodermal tumors. |
||
Monoclonal Ep-CAM / CD326 (Epithelial Marker) Antibody - Without BSA and Azide, Clone: PAN-EpCAM (Cocktail) |
||
| AMM00998G | 0.1mg | EUR 580.8 |
|
Description: A Monoclonal antibody against Human Ep-CAM / CD326 (Epithelial Marker) - Without BSA and Azide. The antibodies are raised in Mouse and are from clone PAN-EpCAM (Cocktail). This antibody is applicable in WB, IHC and IF, FC |
||
CD117(Cocktail) Antibody |
||
| BNC401018-100 | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD117(Cocktail), CF640R conjugate, Concentration: 0.1mg/mL |
||
CD117(Cocktail) Antibody |
||
| BNC401018-500 | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD117(Cocktail), CF640R conjugate, Concentration: 0.1mg/mL |
||
CD117(Cocktail) Antibody |
||
| BNC551018-100 | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD117(Cocktail), CF555 conjugate, Concentration: 0.1mg/mL |
||
CD117(Cocktail) Antibody |
||
| BNC551018-500 | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD117(Cocktail), CF555 conjugate, Concentration: 0.1mg/mL |
||
CD117(Cocktail) Antibody |
||
| BNC431018-100 | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD117(Cocktail), CF543 conjugate, Concentration: 0.1mg/mL |
||
CD117(Cocktail) Antibody |
||
| BNC431018-500 | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD117(Cocktail), CF543 conjugate, Concentration: 0.1mg/mL |
||
CD117(Cocktail) Antibody |
||
| BNC471018-100 | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD117(Cocktail), CF647 conjugate, Concentration: 0.1mg/mL |
||
CD117(Cocktail) Antibody |
||
| BNC471018-500 | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD117(Cocktail), CF647 conjugate, Concentration: 0.1mg/mL |
||